Compare Stocks: QTTB, SEPN, IMCR, and RXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCR Immunocore	$37.12 -0.7%	$33.48	$27.56 ▼ $40.71	$1.93B	0.74	427,165 shs	255,159 shs
QTTB Q32 Bio	$16.18 -0.9%	$14.75	$1.62 ▼ $23.57	$485.84M	0.23	461,048 shs	327,073 shs
RXRX Recursion Pharmaceuticals	$3.49 -2.0%	$3.31	$2.77 ▼ $7.18	$1.91B	1.03	15.88 million shs	12.88 million shs
SEPN Septerna	$40.25 -2.5%	$37.15	$11.70 ▼ $51.10	$1.93B	2.29	456,759 shs	168,409 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCR Immunocore	+2.16%	+3.83%	+6.86%	+31.14%	+14.76%
QTTB Q32 Bio	-0.24%	+6.74%	+7.72%	+27.00%	+728.43%
RXRX Recursion Pharmaceuticals	+9.54%	+15.21%	+20.27%	+12.30%	-26.29%
SEPN Septerna	+1.92%	-5.71%	+24.77%	+38.64%	+245.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCR Immunocore	$37.12 -0.7%	$33.48	$27.56 ▼ $40.71	$1.93B	0.74	427,165 shs	255,159 shs
QTTB Q32 Bio	$16.18 -0.9%	$14.75	$1.62 ▼ $23.57	$485.84M	0.23	461,048 shs	327,073 shs
RXRX Recursion Pharmaceuticals	$3.49 -2.0%	$3.31	$2.77 ▼ $7.18	$1.91B	1.03	15.88 million shs	12.88 million shs
SEPN Septerna	$40.25 -2.5%	$37.15	$11.70 ▼ $51.10	$1.93B	2.29	456,759 shs	168,409 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCR Immunocore	+2.16%	+3.83%	+6.86%	+31.14%	+14.76%
QTTB Q32 Bio	-0.24%	+6.74%	+7.72%	+27.00%	+728.43%
RXRX Recursion Pharmaceuticals	+9.54%	+15.21%	+20.27%	+12.30%	-26.29%
SEPN Septerna	+1.92%	-5.71%	+24.77%	+38.64%	+245.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMCR Immunocore	2.69	Moderate Buy	$56.38	51.87% Upside
QTTB Q32 Bio	2.71	Moderate Buy	$31.00	91.59% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	130.95% Upside
SEPN Septerna	2.82	Moderate Buy	$52.44	30.30% Upside

Current Analyst Ratings Breakdown

Latest QTTB, SEPN, IMCR, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	QTTB Q32 Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$34.00
8/24/2026	IMCR Immunocore	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/21/2026	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$50.00
8/19/2026	SEPN Septerna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$38.00 ➝ $48.00
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/13/2026	SEPN Septerna	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$43.00 ➝ $62.00
8/12/2026	SEPN Septerna	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $50.00
8/12/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
8/11/2026	SEPN Septerna	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$49.00
8/11/2026	SEPN Septerna	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMCR Immunocore	$400.02M	4.78	N/A	N/A	$8.15 per share	4.55
QTTB Q32 Bio	$53.74M	8.96	$1.50 per share	10.76	$3.56 per share	4.54
RXRX Recursion Pharmaceuticals	$74.68M	25.02	N/A	N/A	$1.71 per share	2.04
SEPN Septerna	$45.95M	40.89	N/A	N/A	$8.29 per share	4.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMCR Immunocore	-$35.51M	-$0.37	N/A	148.48	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
QTTB Q32 Bio	$29.82M	$3.00	5.39	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.57%	-6.28%	11/9/2026 (Estimated)

Latest QTTB, SEPN, IMCR, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMCR Immunocore	0.94	4.47	4.44
QTTB Q32 Bio	N/A	20.30	20.30
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
SEPN Septerna	N/A	4.99	4.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMCR Immunocore	84.50%
QTTB Q32 Bio	31.32%
RXRX Recursion Pharmaceuticals	89.06%
SEPN Septerna	N/A

Insider Ownership

Company	Insider Ownership
IMCR Immunocore	10.10%
QTTB Q32 Bio	34.46%
RXRX Recursion Pharmaceuticals	6.65%
SEPN Septerna	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMCR Immunocore	320	51.50 million	46.30 million	Optionable
QTTB Q32 Bio	39	29.77 million	19.51 million	N/A
RXRX Recursion Pharmaceuticals	400	535.34 million	499.74 million	Optionable
SEPN Septerna	N/A	46.68 million	43.97 million	N/A

QTTB, SEPN, IMCR, and RXRX Headlines

Recent News About These Companies

Elmind Capital LP Purchases New Holdings in Septerna, Inc. $SEPN

August 26 at 4:40 AM | marketbeat.com

ADAR1 Capital Management LLC Buys New Stake in Septerna, Inc. $SEPN

August 26 at 3:19 AM | marketbeat.com

Algert Global LLC Grows Stake in Septerna, Inc. $SEPN

August 26 at 3:04 AM | marketbeat.com

Septerna names Rajiv Patni as CMO

August 25 at 12:35 PM | msn.com

Septerna Appoints Rajiv Patni as Chief Medical Officer

August 25 at 8:51 AM | tipranks.com

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

August 25 at 8:00 AM | globenewswire.com

Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 22, 2026 | marketbeat.com

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock

August 21, 2026 | americanbankingnews.com

Septerna (NASDAQ:SEPN) Stock Price Down 8% - Time to Sell?

August 20, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Price Target Raised to $48.00

August 19, 2026 | marketbeat.com

4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC

August 19, 2026 | marketbeat.com

Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN

August 19, 2026 | marketbeat.com

Research Analysts Set Expectations for Septerna Q3 Earnings

August 16, 2026 | americanbankingnews.com

37,700 Shares in Septerna, Inc. $SEPN Purchased by Renaissance Technologies LLC

August 15, 2026 | marketbeat.com

Major Insider Move Shakes Up Septerna, Inc. Shares

August 14, 2026 | tipranks.com

HC Wainwright Predicts Septerna's Q3 Earnings (NASDAQ:SEPN)

August 14, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares

August 14, 2026 | insidertrades.com

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares of Stock

August 13, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Trading Down 6.1% - Here's Why

August 13, 2026 | marketbeat.com

JonesTrading Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock

August 13, 2026 | marketbeat.com

Analysts Offer Insights on NA Companies: Septerna, Inc. (SEPN) and Rapid7 (RPD)

August 13, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB, SEPN, IMCR, and RXRX Company Descriptions

Immunocore NASDAQ:IMCR

$37.12 -0.28 (-0.75%)

As of 04:00 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Q32 Bio NASDAQ:QTTB

$16.18 -0.14 (-0.86%)

As of 04:00 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.49 -0.07 (-1.97%)

As of 04:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Septerna NASDAQ:SEPN

$40.25 -1.05 (-2.54%)

As of 04:00 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTTB, SEPN, IMCR, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTTB, SEPN, IMCR, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTTB, SEPN, IMCR, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB, SEPN, IMCR, and RXRX Company Descriptions

Immunocore NASDAQ:IMCR

Q32 Bio NASDAQ:QTTB

Recursion Pharmaceuticals NASDAQ:RXRX

Septerna NASDAQ:SEPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTTB, SEPN, IMCR, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTTB, SEPN, IMCR, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTTB, SEPN, IMCR, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB, SEPN, IMCR, and RXRX Company Descriptions

Immunocore NASDAQ:IMCR

Q32 Bio NASDAQ:QTTB

Recursion Pharmaceuticals NASDAQ:RXRX

Septerna NASDAQ:SEPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools